ARHGDIG: A Potential Drug Target for Various Diseases (G398)

Target Name: ARHGDIG

NCBI ID: G398

ARHGDIG

ARHGDIG: A Potential Drug Target for Various Diseases

ARHGDIG (GDIR3_HUMAN) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has been linked to the development of certain diseases, which has led to its increased interest in potential drug development.

The ARHGDIG gene is located on chromosome 1p36 and encodes for the G protein-coupled receptor GPR35, which is a member of the G protein-coupled receptor family. GPR35 is a key regulator of cell-cell interactions and has been involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling.

The GPR35 receptor is expressed in many different tissues and cells in the body, including the brain, nervous system, and endothelial cells. Its expression has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

ARHGDIG has been identified as a potential drug target or biomarker for various diseases due to its unique genetic mutation. The G protein-coupled receptor GPR35 has been shown to play a key role in the development and progression of certain diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique expression and regulation have led to its increased interest in potential drug development.

One of the key challenges in the development of new drugs is identifying the underlying mechanisms of disease and understanding how specific drugs can modulate the progression of disease. The ARHGDIG gene and its associated diseases provide a unique opportunity to study the role of GPR35 in disease progression and potential drug development.

The ARHGDIG gene has been linked to the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has been shown to play a key role in the development and progression of these diseases.

For example, studies have shown that individuals with the ARHGDIG gene have an increased risk of developing neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This is thought to be due to the effects of the ARHGDIG gene on the GPR35 receptor, which has been linked to the development of these diseases.

In addition, the ARHGDIG gene has also been linked to the development of certain autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel disease. These disorders are characterized by an overactive immune system, which can lead to inflammation and damage to various body parts.

The increased interest in the ARHGDIG gene and its associated diseases has led to its increased potential as a drug target or biomarker. Researchers are now working to develop drugs that can specifically modulate the activity of the GPR35 receptor, with the goal of treating various diseases.

In conclusion, the ARHGDIG gene is a promising drug target or biomarker for various diseases due to its unique genetic mutation and its involvement in the development and progression of these diseases. Further research is needed to understand the full implications of its role in disease and its potential as a drug.

Protein Name: Rho GDP Dissociation Inhibitor Gamma

Functions: Inhibits GDP/GTP exchange reaction of RhoB. Interacts specifically with the GDP- and GTP-bound forms of post-translationally processed Rhob and Rhog proteins, both of which show a growth-regulated expression in mammalian cells. Stimulates the release of the GDP-bound but not the GTP-bound RhoB protein. Also inhibits the GDP/GTP exchange of RhoB but shows less ability to inhibit the dissociation of prebound GTP

The "ARHGDIG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGDIG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets